HLS Therapeutics Inc. (TSE:HLS - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as C$5.45 and last traded at C$5.09, with a volume of 3830 shares trading hands. The stock had previously closed at C$5.03.
HLS Therapeutics Price Performance
The stock has a market cap of C$111.24 million, a price-to-earnings ratio of -5.01 and a beta of 1.07. The stock's 50 day moving average price is C$4.92 and its two-hundred day moving average price is C$4.51. The company has a quick ratio of 1.01, a current ratio of 1.56 and a debt-to-equity ratio of 86.50.
HLS Therapeutics Company Profile
(
Get Free Report)
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.
See Also
Before you consider HLS Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.
While HLS Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
